Qihan Biotech Secures US FDA IND Clearance for Next-Generation Universal CAR-T Therapy QT-019C
Qihan Biotech has received US FDA Investigational New Drug clearance for QT-019C, an off-the-shelf universal CAR-T therapy designed to improve safety, accessibility and treatment outcomes for patients with autoimmune diseases.
Gene Editing Technology | 22/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy